Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
Merck's COVID-19 pill effective against Omicron in lab studies
By REUTERS
12/07/2024 11:15 AM
By REUTERS
12/07/2024 11:08 AM
By REUTERS
12/07/2024 02:22 AM
By REUTERS
12/07/2024 01:58 AM
By REUTERS
12/06/2024 10:25 PM
By WALLA!
12/06/2024 07:57 PM